15 diciembre 2014
A breast cancer specialist and clinical researcher shows that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/whtNKi4G0Io/141215140853.htm
